InBody

041830 · KOSDAQ · Health Care · SMALL CAP

Provisional Q1 2026 results.

InBody filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$47M (+23.1% year on year), operating profit of US$8.95M (+86% year on year) and net income of US$11.2M (+138.1% year on year).

Earnings(Operating results (consolidated) (preliminary) (fair disclosure))· FILED 2026-05-07· RCEPT 20260507900970

US$47MRevenue
+23.1%Revenue vs a year earlier
US$8.95MOperating profit

Converted at 1 USD ≈ ₩1,454.79 (filing-date rate, 2026-05-07 close)

What happened

InBody filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$47M (+23.1% year on year), operating profit of US$8.95M (+86% year on year) and net income of US$11.2M (+138.1% year on year).

These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.

RevenueUS$47M
Revenue vs a year earlier+23.1%
Operating profitUS$8.95M
Net incomeUS$11.2M
PeriodQ1 2026 (consolidated)
Filed2026-05-07, Operating results (consolidated) (preliminary) (fair disclosure)
SourceDART rcept 20260507900970 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-05-07 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.